The respiratory disease specialist took its overall funding to $55m with a $41.4m round led by Novartis Venture Fund.

Orchard Therapeutics has licensed a range of gene therapies from GSK, which will get a 19.9% stake in the company as part of the deal.

Parkwalk Advisors has returned from earlier rounds to help drive the UEA spinout's bid for additional markets for its image augmentation technology.

IP Group has committed a total of $6.6m to a series A round for Enterprise Therapeutics, which had previously attracted capital from Touchstone Innovations.

Rolls-Royce, Boeing and existing investor BAE Systems all contributed to a $37.3m round for advanced engine developer Reaction Engines.

Frontier IP now owns 27.5% of Plymouth's Fieldwork Robotics and has agreed to lend extra development and engineering expertise to the soft robotic arm manufacturer.